Novel Intraocular Pressure-Lowering Agent, Latanoprostene Bunod, Under Review
LONDON, November 8, 2016 /PRNewswire/ --
Robert N Weinreb, Tony Realini, Rohit Varma; US Ophthalmic Review, 2016;9(2):80-7 DOI: https://doi.org/10.17925/USOR.2016.09.02.80
(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
Published recently in US Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Robert N Weinreb et al, discuss the novel intraocular pressure (IOP)-lowering treatment, latanoprostene bunod (LBN). LBN has a dual action in that it enhances aqueous humor outflow via both the uveoscleral and trabecular meshwork pathways. It is undergoing regulatory review by the Food and Drug Administration (FDA) for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). In the dose-ranging VOYAGER study, LBN 0.024%, the lower of the most effective concentrations evaluated, demonstrated significantly greater IOP lowering and comparable side effects compared with latanoprost 0.005%. The recent APOLLO phase III clinical study (n=420) found LBN 0.024% demonstrated significantly greater reductions in IOP than timolol 0.5% in patients with OAG or OHT at various time points over 3 months. The same study found the proportion of patients with IOP ?18 mmHg was significantly greater with LBN 0.024% than with timolol 0.5%. In the LUNAR study (n=420), LBN 0.024% was non-inferior to timolol 0.5% over 3 months' treatment. LBN treatment also resulted in significantly greater IOP lowering than timolol at all time-points with the exception of the first post-baseline assessment. In JUPITER, a study of 130 subjects with OAG or OHT, LBN 0.024% was safe and well tolerated when used for up to a year, and provided significant and sustained IOP reduction. Further, in CONSTELLATION, a study of 25 patients with OHT or OAG, IOP lowering with LBN 0.024% was consistently lower than baseline during both the diurnal/wake and nocturnal/sleep periods whereas timolol 0.5% reduced IOP only during the diurnal period. In addition, LBN 0.024% treatment resulted in a significantly increased diurnal ocular perfusion pressure versus baseline and nocturnal ocular perfusion pressure versus timolol 0.05%. Similarly, in KRONUS, a single-arm, single-center, open label study of 24 healthy Japanese subjects, LBN 0.024% significantly lowered mean IOP over a 24-hour period. Across these studies, LBN has demonstrated a favorable safely profile and good ocular tolerability. It is hypothesized that LBN's dual action on the outflow pathways accounts for the improved efficacy when compared with latanoprost and timolol.
The full peer-reviewed, open-access article is available here:
Disclosure: Robert N Weinreb has been a consultant to Aerie Pharmaceuticals, Alcon, Allergan, Bausch & Lomb, and ForSightV. He has received research grants from Genentech and Quark and research instruments from Heidelberg Engineering, Optovue, Topcon, and Zeiss. Tony Realini has been a consultat to Alcon, Bausch & Lomb/Valeant, Envisia, Inotek, and Smith and Nephew, and received research support from Alcon, Roche, and Aerie. Rohit Varma has been a consultant to Aerie Pharmaceuticals, Allergan, Bausch & Lomb, Genentech, and Isarna. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.
Note to the Editor
touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the US Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
For inquires please contact: Nicola Cartridge - Managing Editor email@example.com
Providing practical opinion to support best practice for busy healthcare professionals